Literature DB >> 15060710

An electronic pressure-meter nociception paw test for mice.

T M Cunha1, W A Verri, G G Vivancos, I F Moreira, S Reis, C A Parada, F Q Cunha, S H Ferreira.   

Abstract

The aim of the present investigation was to describe and validate an electronic mechanical test for quantification of the intensity of inflammatory nociception in mice. The electronic pressure-meter test consists of inducing the animal hindpaw flexion reflex by poking the plantar region with a polypropylene pipette tip adapted to a hand-held force transducer. This method was compared to the classical von Frey filaments test in which pressure intensity is automatically recorded after the nociceptive hindpaw flexion reflex. The electronic pressure-meter and the von Frey filaments were used to detect time versus treatment interactions of carrageenin-induced hypernociception. In two separate experiments, the electronic pressure-meter was more sensitive than the von Frey filaments for the detection of the increase in nociception (hypernociception) induced by small doses of carrageenin (30 microg). The electronic pressure-meter detected the antinociceptive effect of non-steroidal drugs in a dose-dependent manner. Indomethacin administered intraperitoneally (1.8-15 mg/kg) or intraplantarly (30-300 microg/paw) prevented the hypersensitive effect of carrageenin (100 microg/paw). The electronic pressure-meter also detected the hypernociceptive effect of prostaglandin E2 (PGE2; 10-100 ng) in a dose-dependent manner. The hypernociceptive effect of PGE2 (100 ng) was blocked by dipyrone (160 and 320 microg/paw) but not by intraplantar administration of indomethacin (300 microg/paw). The present results validate the use of the electronic pressure-meter as more sensitive than the von Frey filaments in mice. Furthermore, it is an objective and quantitative nociceptive test for the evaluation of the peripheral antinociceptive effect of anti-inflammatory analgesic drugs, which inhibit prostaglandin synthesis (indomethacin) or directly block the ongoing hypernociception (dipyrone).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15060710     DOI: 10.1590/s0100-879x2004000300018

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  85 in total

1.  Growth Factor Signaling Regulates Mechanical Nociception in Flies and Vertebrates.

Authors:  Roger Lopez-Bellido; Stephanie Puig; Patrick J Huang; Chang-Ru Tsai; Heather N Turner; Michael J Galko; Howard B Gutstein
Journal:  J Neurosci       Date:  2019-05-28       Impact factor: 6.167

2.  Involvement of Endothelin Receptors in Peripheral Sensory Neuropathy Induced by Oxaliplatin in Mice.

Authors:  Renata Bessa Pontes; Mario Roberto Pontes Lisboa; Anamaria Falcão Pereira; Juliana Arcanjo Lino; Francisco Fábio Bezerra de Oliveira; Aline Kelly Viana de Mesquita; Bruno Wesley de Freitas Alves; Roberto César Pereira Lima-Júnior; Mariana Lima Vale
Journal:  Neurotox Res       Date:  2019-06-21       Impact factor: 3.911

3.  Linalool and linalool complexed in β-cyclodextrin produce anti-hyperalgesic activity and increase Fos protein expression in animal model for fibromyalgia.

Authors:  Simone S Nascimento; Enilton A Camargo; Josimari M DeSantana; Adriano A S Araújo; Paula P Menezes; Waldecy Lucca-Júnior; Ricardo L C Albuquerque-Júnior; Leonardo R Bonjardim; Lucindo J Quintans-Júnior
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-06-24       Impact factor: 3.000

4.  Pyrrolidine dithiocarbamate inhibits superoxide anion-induced pain and inflammation in the paw skin and spinal cord by targeting NF-κB and oxidative stress.

Authors:  Felipe A Pinho-Ribeiro; Victor Fattori; Ana C Zarpelon; Sergio M Borghi; Larissa Staurengo-Ferrari; Thacyana T Carvalho; Jose C Alves-Filho; Fernando Q Cunha; Thiago M Cunha; Rubia Casagrande; Waldiceu A Verri
Journal:  Inflammopharmacology       Date:  2016-05-09       Impact factor: 4.473

5.  The specialised pro-resolving lipid mediator maresin 1 reduces inflammatory pain with a long-lasting analgesic effect.

Authors:  Victor Fattori; Felipe A Pinho-Ribeiro; Larissa Staurengo-Ferrari; Sergio M Borghi; Ana C Rossaneis; Rubia Casagrande; Waldiceu A Verri
Journal:  Br J Pharmacol       Date:  2019-04-15       Impact factor: 8.739

6.  Targeting endothelin ETA and ETB receptors inhibits antigen-induced neutrophil migration and mechanical hypernociception in mice.

Authors:  Waldiceu A Verri; Thiago M Cunha; Danilo A Magro; Ana T G Guerrero; Silvio M Vieira; Vanessa Carregaro; Guilherme R Souza; Maria das Graças M O Henriques; Sérgio H Ferreira; Fernando Q Cunha
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-15       Impact factor: 3.000

7.  The leguminous lectin of Lonchocarpus araripensis promotes antinociception via mechanisms that include neuronal inhibition of Na(+) currents.

Authors:  Renata Morais Ferreira Amorim; Alana Freitas Pires; Tiago Dos Santos-Nascimento; Benildo S Cavada; Kyria Santiago do Nascimento; João Batista Cajazeiras; José Henrique Leal-Cardoso; Mário Rogério Lima Mota; Ana Maria S Assreuy
Journal:  Inflamm Res       Date:  2016-05-18       Impact factor: 4.575

8.  Recombinant ecto-5'-nucleotidase (CD73) has long lasting antinociceptive effects that are dependent on adenosine A1 receptor activation.

Authors:  Nathaniel A Sowa; Meagen K Voss; Mark J Zylka
Journal:  Mol Pain       Date:  2010-04-14       Impact factor: 3.395

9.  Caspase-1 is involved in the genesis of inflammatory hypernociception by contributing to peripheral IL-1β maturation.

Authors:  Thiago M Cunha; Jhimmy Talbot; Larissa G Pinto; Silvio M Vieira; Guilherme R Souza; Ana T Guerrero; Fabiane Sonego; Waldiceu A Verri; Dario S Zamboni; Sergio H Ferreira; Fernando Q Cunha
Journal:  Mol Pain       Date:  2010-10-04       Impact factor: 3.395

10.  Recombinant mouse PAP has pH-dependent ectonucleotidase activity and acts through A(1)-adenosine receptors to mediate antinociception.

Authors:  Nathaniel A Sowa; Kunjumon I Vadakkan; Mark J Zylka
Journal:  PLoS One       Date:  2009-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.